Doxorubicin, Paclitaxel, and Carboplatin in Treating Patients With Primary Stage III, Stage IV, or Recurrent Endometrial Cancer
Endometrial Cancer
About this trial
This is an interventional treatment trial for Endometrial Cancer focused on measuring stage III endometrial carcinoma, stage IV endometrial carcinoma, recurrent endometrial carcinoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically proven primary stage III or IV or recurrent endometrial cancer Bidimensionally measurable disease by x-ray, CT scan, MRI scan, or physical exam Sole site may be within a previously irradiated area if documented disease progression since prior radiotherapy PATIENT CHARACTERISTICS: Age: Adult Performance status: Karnofsky 70-100% Life expectancy: At least 12 weeks Hematopoietic: Absolute neutrophil count greater than 1,000/mm^3 Platelet count at least 100,000/mm^3 Hepatic: Bilirubin, SGOT, and alkaline phosphatase no greater than 1.5 times normal Renal: Creatinine no greater than 1.8 mg/dL Cardiovascular: Left ventricular ejection fraction at least 50% Other: No active uncontrolled infection No greater than grade II neuropathy No other active malignancy Not pregnant Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior doxorubicin Greater than 6 months since prior paclitaxel, carboplatin, or other platinum compounds Endocrine therapy: Not specified Radiotherapy: See Disease Characteristics At least 4 weeks since prior radiotherapy and recovered Surgery: Not specified
Sites / Locations
- Memorial Sloan-Kettering Cancer Center